Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

The court also asked Dr Reddy’s to inform it by Friday whether it is willing to drop the “Olymviq” brand name, as the matter centres around alleged trademark similarity with Novo Nordisk’s widely known drug Ozempic.

The Delhi High Court  has orally directed Dr. Reddy’s Laboratories on Wednesday to halt the market launch and sales of its drug branded as “Olymviq” until Friday, in a trademark dispute with Novo Nordisk.

The court also asked Dr Reddy’s to inform it by Friday whether it is willing to drop the “Olymviq” brand name, as the matter centres around alleged trademark similarity with Novo Nordisk’s widely known drug Ozempic.

This comes after the High Court earlier this month backed Dr Reddy’s Laboratories in its legal dispute with Novo Nordisk regarding the export and manufacture of semaglutide, a key ingredient for drugs such as Ozempic and Wegovy that are used in diabetes and chronic weight management respectively.

During the hearing, the Delhi High Court flagged the phonetic and visual similarity between the names “Olymviq” and “Ozempic”, and said the similarity could potentially lead to consumer confusion, particularly in the pharmaceutical market where brand names play a critical role in prescriptions and dispensing.

Novo Nordisk has alleged that the name “Olymviq” is deceptively similar to “Ozempic” and has sought an injunction to restrain Dr Reddy’s from using the brand name. The company argued that such similarity could create confusion among patients, pharmacists, and doctors.

The court issued an interim direction restricting the launch and sale of Olymviq and asked Dr Reddy’s to respond to the allegations. The court clarified that the case is centred on trademark similarity and brand confusion, and not a patent dispute.

Ozemvic, manufactured by Novo Nordisk, is a widely used diabetes drug that is also prescribed for weight loss in many markets, making the brand highly recognisable globally.

The matter has been listed for further hearing in the coming days, and the court is expected to take a view after hearing Dr Reddy’s response on the branding issue.

Related Posts

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

The Court observed that the alleged short supply of one tablet, coupled with the collection of ₹1.12, did not establish that the accused had sold the drug at a price…

Fake epilepsy, diabetes drugs made using chalk, lactose at illegal Himachal factory; 2 held

MEERUT/SHIMLA: An illegal pharmaceutical factory allegedly manufacturing counterfeit medicines used to treat epilepsy, diabetes, typhoid and other ailments using substances such as chalk and lactose was busted in Himachal Pradesh’s…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

Fake epilepsy, diabetes drugs made using chalk, lactose at illegal Himachal factory; 2 held

Fake epilepsy, diabetes drugs made using chalk, lactose at illegal Himachal factory; 2 held

Without Skipping a Beat: Surgical Robot SSiMantra powers Landmark Beating Heart Bypass

Without Skipping a Beat: Surgical Robot SSiMantra powers Landmark Beating Heart Bypass

Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines

Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines

‘Forthwith’ Under Drugs Act Does Not Mean Immediate Dispatch of Seized Drug Samples: Karnataka HC

‘Forthwith’ Under Drugs Act Does Not Mean Immediate Dispatch of Seized Drug Samples: Karnataka HC

A Worthy New Leader takes the Torch @Sir Ganga Ram Hospital

A Worthy New Leader takes the Torch @Sir Ganga Ram Hospital